Home›Trial›NCT06921837
🔬NCT06921837Phase 1Phase 2RECRUITING

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

Study Summary

A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers

Conditions
Gastric Cancer Adenocarcinoma MetastaticGastroesophageal Adenocarcinoma
Interventions / Drugs
BDC-4182
View on ClinicalTrials.gov ↗
Sponsor
BOLT
Bolt Biotherapeutics
Oncology
D38/100
Study Details
Enrollment122 participants
Primary Completion—
Lead SponsorBolt Biotherapeutics, Inc.
Data Retrieved2026-04-11 04:08:22.049316+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.